ChatGPTを活用して業務のAI化を進めています。プロンプトエンジニアリングの専門家です！と、名乗れるレベルではありませんが、かなり色々使いこなしてきています。この１年、病気で失われた能力は、別な能力を発達させる、進化することで生き残っていこうと思います。
<><><>
23/07/01
Dyspnea Associates With a Widely Impaired Quality of Life in Idiopathic Pulmonary Fibrosis Patients: A Longitudinal Study Using 15D
T Rautajoki, JT Lehto, E Sutinen, P Bergman… - Journal of Palliative …, 2023
Background: Research on health-related quality of life (HRQoL) is crucial for developing comprehensive palliative care in idiopathicpulmonary fibrosis (IPF). Objectives: To study IPF patients' HRQoL compared with general population and its …
- 呼吸困難は特発性肺線維症患者の広範な生活の質の低下と関連している: 15D を使用した縦断研究
[HTML] Identification of potential biomarkers for idiopathic pulmonary fibrosis and validation of TDO2 as a potential therapeutic target
R Wang, YM Yang - World Journal of Cardiology, 2023
… Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease with a high mortality rate. On this basis, exploring potential therapeutic targets to meet the unmet needs of … Core Tip: This study is unique in several aspects: (1) We …
[PDF] Comprehensive biomarker analysis of patients with idiopathic pulmonary fibrosis and interstitial lung disease with healthy individuals
A Balci, ME Düz, A Vurmaz, Ş Çilekar, F Kaya - European Review for Medical and …, 2023
… Several indicators are essential in diagnosing these individuals and differentiating between IPFand ILD. PATIENTS AND METHODS: The study involved 44 IPF patients, 22 ILD (non-IPF) patients, and 24 healthy people. We aimed to …
- 特発性肺線維症および間質性肺疾患患者と健常者の包括的なバイオマーカー解析 リラキシンを配合した吸入多孔質ミクロスフェアは、特発性肺線維症を抑制し、ブレオマイシン後の肺機能を改善します
Relaxin-Loaded Inhaled Porous Microspheres Inhibit Idiopathic Pulmonary Fibrosis and Improve Pulmonary Function Post-Bleomycin Challenges
S Qiu, X Fu, Y Shi, H Zang, Y Zhao, Z Qin, G Lin… - Molecular Pharmaceutics, 2023
Idiopathic pulmonary fibrosis (IPF) causes worsening pulmonary function, and no effective treatment for the disease etiology is available now. Recombinant Human Relaxin-2 (RLX), a peptide agent with anti-remodeling and anti-fibrotic effects, is a …
- リラキシンを配合した吸入多孔質ミクロスフェアは、特発性肺線維症を抑制し、ブレオマイシン後の肺機能を改善します
[HTML] Using group based trajectory modeling for assessing medication adherence to nintedanib among idiopathic pulmonary fibrosis patients
M Nili, AJ Epstein, D Nunag, A Olson, B Borah - BMC Pulmonary Medicine, 2023
… Individuals with idiopathic pulmonaryfibrosis (IPF) who initiated nintedanib during 10/1/2014–12/31/2018 were identified in 100% Medicare … Idiopathic pulmonary fibrosis(IPF) is a rare interstitial lung disease that is accompanied by a …
Genetic overlap study between idiopathic pulmonary fibrosis and COVID-19
B Guillen-Guio, R Allen, E Croot, S Moss, I Stewart… - European Journal of Human …, 2023
… Genetic factors influence COVID-19 susceptibility and outcomes, including the development of pulmonary fibrosis (ie lung scarring). Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease and the most common cause of pulmonary fibrosis in …
Tobacco Smoking is Associated with Combined Pulmonary Fibrosis and Emphysema and Worse Outcomes in Interstitial Lung Disease
D Douglas, L Keating, R Strykowski, CT Lee, N Garcia… - American Journal of …, 2023
… Smokers were more likely to 71 be older, male, have idiopathic pulmonary fibrosis (PF), coronary artery disease, CT 72 honeycombing and emphysema, higher FVC, and lower DLCO than non-smokers(P<0.01). 73 Time to LFD in smokers was …
- 喫煙は複合型肺線維症と肺気腫、および間質性肺疾患の悪化と関連している
Comment on: Anti-acid therapy in SSc-associated interstitial lung disease: long-term outcomes from the German network for systemic sclerosis
O Moran-Mendoza, A Al-Jarallah, S Alqahtani… - Rheumatology, 2023
… The 2022 idiopathic pulmonary fibrosis(IPF) and progressive pulmonary fibrosisguidelines (2) - based on limited available evidence - suggested that antacid medication may be appropriate for patients with IPF and symptoms of GERD for the …
- コメント: SSc 関連間質性肺炎における抗酸療法: ドイツの全身性硬化症ネットワークからの長期結果
Deep Learning Assessment of Progression of Emphysema and Fibrotic Interstitial Lung Abnormality
SY Ash, B Choi, A Oh, DA Lynch, SM Humphries… - American Journal of …, 2023
… in individuals with idiopathic pulmonaryfibrosis is approximately 3.4%.(4, 11, 12) However, the MCID for DTA in individuals without known pulmonary fibrosis is unknown. The purposes of this study were to determine the MCID of quantitative …
- 肺気腫および線維性間質性肺異常の進行の深層学習評価
23/06/27
A fibroblastic foci-targeting and hypoxia-cleavable delivery system of pirfenidone for the treatment of idiopathic pulmonary fibrosis
T Zhao, B Gong, S Luo, R Zhang, L Zhang, Y Huang… - Acta Biomaterialia, 2023
… of fibroblastic foci characterizes idiopathicpulmonary fibrosis (IPF), … IPF, leading to alveolar dysfunction and deeper cellular fibrosis. Herein, a fibroblastic foci-targeting and hypoxia-cleavable drug delivery system ([email protected]) was established to …
- 特発性肺線維症の治療のための、線維芽細胞病巣を標的とし、低酸素で切断可能なピルフェニドンの送達システム
[HTML] Preparation and Evaluation of Sustained Release Pirfenidone-Loaded Microsphere Dry Powder Inhalation for Treatment of Idiopathic Pulmonary Fibrosis
S Bao, Y Zou, CK Firempong, Y Feng, Y Yu, Y Wang… - European Journal of …, 2023
Pirfenidone (PFND) is a recommended oral drug used to treat idiopathic pulmonary fibrosis, but have low bioavailability and high hepatotoxicity. The study, therefore, seeks to improve the therapeutic activities of the drug via increased bioavailability …
- 特発性肺線維症の治療のための徐放性ピルフェニドン充填マイクロスフェアドライパウダー吸入の調製と評価
Mendelian randomization study reveals the effect of idiopathic pulmonary fibrosis on the risk of erectile dysfunction
K Zhang, J Zhou, A Li, M Chen - Frontiers in Medicine
… relationship between idiopathic pulmonaryfibrosis (IPF) and ED risk remains unclear. The present two-sample mendelian randomization (MR) study aimed to reveal the causal effect of IPF on ED risk. Methods: This study included two GWAS …
- メンデルランダム化研究により、勃起不全のリスクに対する特発性肺線維症の影響が明らかに
Pulmonary fibrosis and type-17 immunity
S Senoo, H Higo, A Taniguchi, K Kiura, Y Maeda… - Respiratory Investigation, 2023
… Fibrosis of the lung can occur in idiopathicpulmonary fibrosis, collagen vascular diseases, … -17 immunity, which is involved in pulmonaryfibrosis. The components of type-17 immunity … Idiopathic pulmonary fibrosis (IPF) is a progressive disease …
- 肺線維症と 17 型免疫
[PDF] Association between Parenchymal B-Cell Follicles and CT-Proven Enlarged Mediastinal Lymph Nodes in Patients with Pulmonary Fibrosis
SKWEB Line, B Madsenb, FRV Polettia
… Background: Mediastinal lymph node enlargement (MLNE) is a finding described in a subset of patients with idiopathic pulmonaryfibrosis (IPF) and other interstitial lung diseases (ILDs) and is associated with accelerated disease progression and …
- 肺線維症患者における実質B細胞濾胞とCTで証明された縦隔リンパ節の拡大との関連
[HTML] Impact of radiographic honeycombing on transplant free survival and efficacy of immunosuppression in fibrotic hypersensitivity pneumonitis
TN Adams, K Batra, M Kypreos, CS Glazer - BMC Pulmonary Medicine, 2023
… The distinction between hypersensitivity pneumonitis (HP) and idiopathic pulmonaryfibrosis (IPF) was thought to be important due to the difference in mortality between the conditions as well as the response to treatment. However …
Drug like HSP27 Cross linkers with Chromenone structure Ameliorates Pulmonary Fibrosis
Y Yoo, S Jeon, H Jin, HY Won, MG Jeong, Y Cho… - Frontiers in Pharmacology
… So far, two drugs, pirfenidone, and nintedanib, have been approved for patients with idiopathicpulmonary fibrosis (IPF). Unfortunately, such drugs simply delay the occurrence of fibrosis and hence do not constitute a treatment for this illness. Heat …
- HSP27 のような薬物 クロメノン構造を持つ架橋剤が肺線維症を改善
Mesenchymal stem cells and pulmonary fibrosis: a bibliometric and visualization analysis of literature published between 2002 and 2021
Y Yang, Y Chen, Y Liu, Z Ning, Z Zhang, Y Zhang, K Xu… - Frontiers in Pharmacology
… Pulmonary fibrosis (PF) is a severe disease that can lead to respiratory failure and even death. However, currently there is no effective … had the most related studies; 4) Keywords, such as idiopathic pulmonary fibrosis, MSCs, and systemic …
- 間葉系幹細胞と肺線維症: 2002 年から 2021 年に出版された文献の書誌学的分析および視覚化分析
MCP1 as a prognostic biomarker in Hypersensitivity Pneumonitis: a prospective study
ACGF Pinto - 2023
… Both elevated circulating monocytes and alveolar macrophages have been pointed to play a role in the pathogenesis of idiopathicpulmonary fibrosis (IPF), but no substantive data exists regarding their contribution on PF-HP. We hypothesized …
- 過敏性肺炎の予後バイオマーカーとしての MCP1: 前向き研究
[PDF] Characterization of channeling effects applied to extended-release matrix tablets containing pirfenidone
J Kang, SD Yoo, KH Han, SJ Jeong, HJ Lee, JH Yoo… - … and Pharmaceutical Bulletin, 2023
… Idiopathic pulmonary fibrosis (IPF) is a condition with unknown etiology, which is unresponsive to treatment; however, IPF is the most common type of idiopathic interstitial pneumonia. IPF has been classified as an orphan disease and occurs at a …
<><><>
特発性肺線維症( idiopathic pulmonary fibrosis (IPF) )関連の学術的情報収集してシェアしています。Google Scholar SearchのUpdateを定期的に掲載しています。GoogleのAIが一定の重み付けはしているとは思いますが、玉石混交です。
当面、毎週アラートの内容をアップしていこうと思います。
###
